Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

NCT02766543 is registered in ClinicalTrials.gov with Profound Medical Inc. as lead sponsor.

NCT NCT02766543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02766543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
Lead sponsor
Profound Medical Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 21, 2016
Completion date
September 30, 2028
Enrollment
150 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer